SuperPathway Analyses of Luminal and Basaloid Breast Cancers... - Christopher Benz
Advancing Our Understanding of Basal-Like, Luminal A, and Luminal B Breast Cancers
pSTAT3 in luminal breast cancer - results from BIG-2-98 trial
Neil Barth, Agendia: Molecular Subtypes in Breast Cancer Challenging the Clinical Subtyping Paradigm
Women with luminal A breast cancer subtype do not seem to benefit from adjuvant chemotherapy
Heterogeneity in treatment response in patients with luminal breast cancer (Matthew Ellis, USA
Luminal breast cancer: what's new in understanding protocol design, efficacy and toxicity assessment
Molecular Subtyping with Breast Cancer
The role of immunotherapy in endocrine-refractory luminal breast cancer
Helga Christl, luminal A breast cancer survivor
Managing Luminal A and Luminal B Breast Cancer
FOXA1 pathway and its role in breast cancer explained
Dr. Perou Reflects on Research Leading Intrinsic Subtypes in Breast Cancer
Gene Expression Algorithm for Prioritizing Treatment Options in BRCA1/2 Carriers with Breast Cancer
Efficacy and gene expression results from eribulin SOLTI1007 neoadjuvant study
Dr. Michael Gnant on the PAM50 Breast Cancer Intrinsic Subtypes
Genome - Cancer Subtype Relationships - Strata Ignite 2013
Dr. Nielsen Discusses the PAM50 Assay
Carlos Caldas: Stratification of breast cancer into 10 genomic driver-based subtypes...
Impact of liquid biopsy in advanced HER2 breast cancer tumors: a follow-up study